Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01727778 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Drug Safety

Interventions

BIOLOGICAL: Anti-GRP78 monoclonal IgM antibody PAT-SM6

Sponsor

Patrys Ltd.